SEC Info - Paratek Pharmaceuticals, Inc. - ‘S-4MEF’ on 10/27/14

SEC Info℠

Home

Help

Please Sign In

Paratek Pharmaceuticals, Inc. – ‘S-4MEF’ on 10/27/14 – ‘EX-99.1’

On: Monday, 10/27/14, at 8:58pm ET · Effective: 10/27/14 · Accession #: 1193125-14-383742 · File #s: 333-198464, 333-199624

  As Of                Filer                Filing    For·On·As Docs:Size              Issuer               Agent

10/27/14  Paratek Pharmaceuticals, Inc.     S-4MEF     10/27/14   12:143K                                   Donnelley … Solutions/FA

Registration of Additional Securities — Form S-4
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: S-4MEF      Registration of Additional Securities               HTML     44K 
 2: EX-5.1      Opinion re: Legality                                HTML     18K 
 3: EX-8.1      Opinion re: Tax Matters                             HTML     22K 
 4: EX-8.2      Opinion re: Tax Matters                             HTML     18K 
 5: EX-23.1     Consent of Experts or Counsel                       HTML      7K 
 6: EX-23.2     Consent of Experts or Counsel                       HTML      8K 
 7: EX-99.1     Miscellaneous Exhibit                               HTML      7K 
 8: EX-99.2     Miscellaneous Exhibit                               HTML      8K 
 9: EX-99.3     Miscellaneous Exhibit                               HTML      8K 
10: EX-99.4     Miscellaneous Exhibit                               HTML      8K 
11: EX-99.5     Miscellaneous Exhibit                               HTML      8K 
12: EX-99.6     Miscellaneous Exhibit                               HTML      8K

EX-99.1 — Miscellaneous Exhibit

This Exhibit is an HTML Document rendered as filed. [ Alternative Formats ]

EX-99.1

Exhibit 99.1

CONSENT OF LEERINK PARTNERS LLC

We hereby consent to the use of our opinion letter dated June 30, 2014 to the Board of Directors of Transcept Pharmaceuticals, Inc. (“Transcept”), included as Annex B to Transcept’s joint proxy statement/prospectus that forms part of the registration statement on Form S-4 filed with the Securities and Exchange Commission as of the date hereof, which such registration statement incorporates by reference Transcept’s registration statement on Form S-4, as amended (Registration No. 333-198464), declared effective October 1, 2014, relating to the proposed issuance by Transcept of shares of its common stock in connection with the merger of Transcept’s wholly owned subsidiary, Tigris Merger Sub, Inc., with and into Paratek Pharmaceuticals, Inc., and to the references to such opinion therein.

Date: October 27, 2014

LEERINK PARTNERS LLC

/s/ John I. Fitzgerald, Esq.

By: John I. Fitzgerald, Esq.

Managing Director

Dates Referenced Herein and Documents Incorporated by Reference

This ‘S-4MEF’ Filing	Date	Other Filings

Filed on / Effective on:	10/27/14
	10/1/14
	6/30/14	10-Q, 8-K
		List all Filings

↑Top